Conclusion of non-exclusive pharmaceutical rebate agreements for tiotropium bromide inhalation solution

Summary

The procurement concerns non-exclusive rebate agreements for inhalation solutions containing tiotropium bromide, offered through an open-house participation model. The quantity of medicines supplied will depend on demand and on prescribing, dispensing and pharmacy stocking practices; no minimum purchase quantity is guaranteed. The agreements will run no later than 31 December 2028, although the procedure may be ended earlier.